CD19 and diffuse large B-cell lymphoma: Loncastuximab tesirine (Lonca) is an antibody–drug conjugate targeting CD19, approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after ≥ 2 prior therapies.